Is Jazz Pharmaceuticals PLC (JAZZ) a risky stock?
As of July 24, 2026, Clavix grades Jazz Pharmaceuticals PLC (JAZZ) B+ for risk, a composite score of 78 out of 100 on an A+ to F scale, which puts JAZZ in the "solid" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 24, 2026. Clavix regrades every trading day.
The five risk dimensions behind JAZZ's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how JAZZ scores on each, as of July 24, 2026.
What's moving JAZZ's risk right now
Company-specific signals Clavix flags behind JAZZ's current grade, drawn from recent news and filings as of July 24, 2026.
UBS says the Ziihera launch in GEA will matter more than Q2 results for the stock. Jazz is also exiting Sunosi to narrow its sleep-disorder portfolio, which frees up capital but trims near-term revenue diversification.
SEB Asset Management bought a new position in JAZZ shares in Q1, according to a 13F filing. Separately, sector data flags antibody-therapeutics dealmaking as a track item for biotech investors.
Canaccord Genuity upgraded JAZZ's stock rating, which can draw in more institutional buyers and signals confidence in the near-term outlook. The specific reasoning behind the upgrade wasn't detailed in the data.
Recent JAZZ news
The latest headlines Clavix ingested for Jazz Pharmaceuticals PLC, newest first. These feed the news-sentiment dimension of JAZZ's grade.
-
Jazz Pharmaceuticals (JAZZ) has a strong track record of beating earnings estimates and currently meets two key criteria that historically predict a positive earnings surprise in its upcoming quarterly report.
What a B+ grade means
On the Clavix A+ to F scale, JAZZ's composite of 78 falls in the B band (65–79), read as "solid." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell JAZZ or any security. Grades are risk indicators, not predictions of return. Data may be delayed.